<DOC>
	<DOCNO>NCT00004930</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : Phase I trial study effectiveness inhale doxorubicin treat patient primary lung cancer lung metastasis .</brief_summary>
	<brief_title>Inhaled Doxorubicin Treating Patients With Primary Lung Cancer Lung Metastases</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose phase II dose inhale doxorubicin administer every 3 week patient primary lung cancer cancer metastatic lung . - Determine toxic effect pharmacokinetic profile regimen patient population . - Examine relationship pharmacodynamic parameter toxic effect regimen patient . - Obtain preliminary evidence therapeutic activity regimen patient . OUTLINE : This dose-escalation study . Patients receive inhale doxorubicin every 3 week . Treatment continue maximum 3 course absence unacceptable toxicity disease progression . Patients may reenter high dose level 3-month waiting period . Cohorts 3-6 patient receive escalate dos doxorubicin maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow 6 week . PROJECTED ACCRUAL : A total 3-36 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary lung cancer cancer metastatic lung potentially curable standard chemotherapy , radiotherapy , surgery Bronchoalveolar cell lung cancer allow Lung metastasis soft tissue sarcoma allow No leukemia lymphoma PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm^3 Platelet count least 160,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.0 mg/dL AST/ALT le 1.5 time upper limit normal Renal : Creatinine great 1.2 mg/dL OR Creatinine clearance least 50 mL/min Cardiovascular : LVEF normal MUGA scan echocardiography No unstable angina No congestive heart failure No symptomatic arrhythmias Pulmonary : DLCO least 65 % normal FVC least 50 % predict FEV1 least 50 % predict Resting oxygen saturation least 90 % Exercise oxygen saturation least 85 % No complete atelectasis No asthma Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 6 month study No congenital problem ( e.g. , cleave palate ) anomaly would prevent tight fit mouth seal No concurrent illness would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 3 week since prior chemotherapy recover No prior bleomycin nitrosoureas No prior mitomycin great 25 mg/m^2 No prior anthracyclines great 450 mg/m^2 No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics At least 3 week since prior radiotherapy recover No prior chest ( pulmonary mediastinal ) thoracic spine radiotherapy Patients chest wall primary breast radiation eligible No concurrent thoracic irradiation Surgery : See Disease Characteristics No prior pneumonectomy Other : No daily necessary respiratory drug via inhaler nebulizer No concurrent experimental drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>extensive stage small cell lung cancer</keyword>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
	<keyword>lung metastasis</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>